

# Saxenda® Dosing Guide

## Initiating treatment with Saxenda® for chronic weight management in adults

Saxenda® (liraglutide injection) is indicated as an adjunct to a reduced calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index (BMI) of:<sup>1</sup>


- 30 kg/m<sup>2</sup> or greater (obesity), or
- 27 kg/m<sup>2</sup> or greater (overweight) in the presence of at least one weight-related comorbidity (e.g., hypertension, type 2 diabetes, or dyslipidemia) and who have failed a previous weight management intervention.



## Simple, once-daily dosing at any time of day, independent of meals<sup>1</sup>

Patients should follow a progressive dose escalation to achieve the maintenance dose of 3.0 mg/day

The dose escalation schedule should be used to reduce the likelihood of gastrointestinal symptoms.




- If patients do not tolerate an increased dose during dose escalation, each step in the dose escalation can be delayed up to 7 days
- If a patient has not lost at least 5% of their initial body weight after 12 weeks on the 3.0 mg maintenance dose, treatment with Saxenda® should be discontinued

Please see the Product Monograph for the complete dosing and administration information.

Demonstrate the first injection in the office to help patients get started

1 attach needle



2 select dose



3 inject dose



4 remove needle



The Saxenda® pen is designed to be used with NovoFine® Plus—a 4 mm, universal pen needle with comfort-base technology so patients can experience a **virtually painless injection**.\*

\* Clinical significance has not been established.



Scan this QR code with your smartphone camera to visit [SaxendaHCP.ca](https://SaxendaHCP.ca) and find out more about Saxenda®



Encourage your patients to enrol in the *SaxendaCare*® Patient Support Program by visiting [SaxendaCare.ca](https://SaxendaCare.ca) today!

Consult the Product Monograph at <https://www.novonordisk.ca/content/dam/nncorp/ca/en/products/saxenda-product-monograph.pdf> for more information on conditions of clinical use, contraindications, warnings and precautions, adverse reactions, drug interactions, and dosing information. The Product Monograph is also available by calling Novo Nordisk at 1-800-465-4334.

Reference:

1. Saxenda® Product Monograph. Novo Nordisk Canada Inc. November 3, 2021.



Saxenda®, SaxendaCare® and NovoFine® Plus are registered trademarks of Novo Nordisk A/S and used under license by Novo Nordisk Canada Inc.  
**Novo Nordisk Canada Inc.**, Tel: (905) 629-4222 or 1-800-465-4334.  
[www.novonordisk.ca](http://www.novonordisk.ca)  
© Novo Nordisk Canada Inc.

CA225X00012E

